ViiV's bimonthly HIV PrEP jab cleared for use by NHS

GSK's ViiV Healthcare has secured key market access for its bimonthly injectable HIV PrEP, Apretude (cabotegravir), with the NHS in England and Wales now offering it as an alternative to daily oral pills following NICE approval. This development expands access for an estimated 1,000 high-risk individuals facing adherence challenges, positioning Apretude as the UK's first approved injectable PrEP and supporting the nation's 2030 HIV transmission elimination goal. The move establishes ViiV's early lead in the injectable PrEP market, ahead of anticipated competition from Gilead Sciences.

Analysis

GSK's ViiV Healthcare has secured significant market access for its bimonthly injectable HIV PrEP, Apretude (cabotegravir), with the NHS in England and Wales now offering it. This follows NICE approval, positioning Apretude as the UK's first approved injectable PrEP and addressing a critical adherence gap for an estimated 1,000 high-risk individuals. The decision aligns England and Wales with Scotland, where Apretude has been available since February.

This development provides GSK with an early mover advantage in the UK's injectable PrEP market, potentially capturing a new segment of patients who struggle with daily oral medication. While Gilead Sciences' lenacapavir is approved elsewhere and expected for UK submission, ViiV's established reimbursement and rollout plan could create a significant barrier to entry for competitors. The product also supports the NHS's ambitious goal of eliminating new HIV cases by 2030, indicating strong governmental backing.

The strongly positive sentiment (0.8) for GSK and moderate market impact (0.55) reflect the strategic importance of this market expansion and the potential for new revenue streams. Apretude's ability to reach patients with adherence challenges expands the total addressable market for PrEP, contributing to ViiV's long-term growth trajectory. This approval solidifies GSK's leadership in the HIV treatment and prevention landscape.

Key Decisions for Investors

• Investors should monitor GSK's Apretude rollout and adoption rates within the NHS, as successful integration could significantly boost ViiV's revenue and market share in the PrEP segment.
• Evaluate the competitive landscape, particularly the timing and success of Gilead Sciences' lenacapavir UK submission, to assess potential future market share erosion for GSK.
• Consider GSK's strengthened position in the HIV prevention market as a long-term growth driver, given the product's unique offering and alignment with public health initiatives.